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The AAA ATPase VPS4 plays an essential role in multivesicular body biogenesis and is thought to act by disassembling
ESCRT-III complexes. VPS4 oligomerization and ATPase activity are promoted by binding to LIP5. LIP5 also binds to the
ESCRT-III like protein CHMP5/hVps60, but how this affects its function remains unclear. Here we confirm that LIP5
binds tightly to CHMP5, but also find that it binds well to additional ESCRT-III proteins including CHMP1B, CHMP2A/
hVps2–1, and CHMP3/hVps24 but not CHMP4A/hSnf7–1 or CHMP6/hVps20. LIP5 binds to a different region within
CHMP5 than within the other ESCRT-III proteins. In CHMP1B and CHMP2A, its binding site encompasses sequences at
the proteins’ extreme C-termini that overlap with “MIT interacting motifs” (MIMs) known to bind to VPS4. We find
unexpected evidence of a second conserved binding site for VPS4 in CHMP2A and CHMP1B, suggesting that LIP5 and
VPS4 may bind simultaneously to these proteins despite the overlap in their primary binding sites. Finally, LIP5 binds
preferentially to soluble CHMP5 but instead to polymerized CHMP2A, suggesting that the newly defined interactions
between LIP5 and ESCRT-III proteins may be regulated by ESCRT-III conformation. These studies point to a role for
direct binding between LIP5 and ESCRT-III proteins that is likely to complement LIP5’s previously described ability to
regulate VPS4 activity.
INTRODUCTION
Multivesicular bodies (MVBs) are a subset of late endosomes
morphologically characterized by the presence of intralume-
nal vesicles (ILVs; Gruenberg, 2004; Piper and Katzmann,
2007). Signaling receptors destined for degradation as well
as certain lysosomal proteins are sorted into ILVs en route to
the lysosome (Katzmann et al., 2002). Protein machinery
involved in MVB biogenesis was discovered in studies of
protein sorting to the vacuole in Saccharomyces cerevisiae.
Functional loss of what are termed the class E Vps (vacuolar
protein sorting) proteins prevents delivery of cargo into the
vacuole. Cargo accumulates instead on the limiting mem-
brane of the vacuole and in an adjacent abnormal compart-
ment referred to as the “class E compartment” (Raymond
et al., 1992). Eighteen class E Vps proteins have been iden-
tified in yeast, and these proteins are highly conserved
throughout evolution (Babst, 2005; Hurley and Emr, 2006;
Saksena et al., 2007). Interestingly, several mammalian class
E Vps proteins are also involved in viral budding and cyto-
kinesis, demonstrating a conserved role in topologically sim-
ilar membrane budding and fission reactions (Demirov and
Freed, 2004; Morita and Sundquist, 2004; Bieniasz, 2006;
Carlton and Martin-Serrano, 2007; Morita et al., 2007).
A majority of class E Vps proteins are components of
four complexes that include Vps27/Hse1 (sometimes re-
ferred to as ESCRT-0), ESCRT-I, ESCRT-II, and ESCRT-III,
where ESCRT is an acronym for endosomal sorting com-
plex required for transport. These complexes are recruited
(possibly sequentially) to endosomal membranes where they
function in sorting cargo and generating ILVs. The AAA
ATPase Vps4 is recruited by ESCRT-III to disassemble and
recycle the ESCRT machinery (Hurley and Emr, 2006; Sak-
sena et al., 2007; Williams and Urbe, 2007).
ESCRT-III components are small (200–250 amino acid)
structurally related proteins. All have basic N-terminal and
acidic C-terminal halves and are thought to share a common
set of six -helices (Muziol et al., 2006; Shim et al., 2007).
There are six ESCRT-III–related proteins in yeast (Vps2,
Vps24, Vps20, and Snf7, core members; and Did2/Vps46
and Vps60, proposed regulatory members), and these are
extended to eleven proteins in humans (Kranz et al., 2001;
Babst et al., 2002; Saksena et al., 2007). Mammalian ESCRT-III
proteins are referred to either as orthologues of their yeast
counterparts or as CHMPs (charged multivesicular body
proteins). To standardize our discussion of the large group
of mammalian ESCRT-III proteins, we will primarily use the
CHMP nomenclature in this article.
Unlike ESCRT-I and -II that are stable heteropolymeric
complexes, ESCRT-III proteins are monomers in the cyto-
plasm and only assemble into complex on the endosomal
membrane (Babst et al., 2002). In current models, ESCRT-III
proteins are maintained in a metastable “closed” conforma-
tion in the cytoplasm and “open” when they bind to the
membrane and assemble into polymers (Hurley and Emr,
2006; Saksena et al., 2007; Williams and Urbe, 2007; Shim
et al., 2007). These polymers may deform the membrane and
participate in forming ILVs (Hanson et al., 2008). Previously
we defined 40 amino acids at the extreme C-terminus of
each core ESCRT-III protein as an autoregulatory domain
that controls transition between these states (Shim et al.,
2007). These 40 amino acids include a short C-terminal -he-
lix and a linker that connects it to the rest of the protein.
ESCRT-III does not spontaneously disassemble, but in-
stead requires energy input from the AAA (ATPases as-
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sociated with a variety of cellular activities) protein Vps4
(Babst et al., 1998), of which there are two isoforms in mam-
malian cells, VPS4A and VPS4B/SKD1. We will use VPS4 to
refer generically to the different forms of this enzyme. VPS4
has recently been shown to bind via its N-terminal micro-
tubule interacting and trafficking (MIT) domain to a short
motif present in a subset of ESCRT-III proteins, including
CHMP1 (Did2 in yeast), CHMP2 (Vps2 in yeast), and
CHMP3 (Vps24 in yeast; Obita et al., 2007; Stuchell-Brereton
et al., 2007). This VPS4 binding motif is in a short C-terminal
-helix and is referred to as the MIT domain–interacting
motif (MIM; Obita et al., 2007). The C-termini of the remain-
ing ESCRT-III proteins (CHMP4 [Snf7 in yeast], CHMP5
[Vps60 in yeast], and CHMP6 [Vps20 in yeast]) do not
contain the conserved MIM despite the fact that some of
them have previously been shown to bind to VPS4 (von
Schwedler et al., 2003; Yeo et al., 2003; Xiao et al., 2007). How
VPS4 interacts with these proteins remains to be deter-
mined.
Although VPS4 activity is essential for MVB biogenesis,
little is known about how it works. The AAA domain of
VPS4 is similar to other AAA domains with the exception
of an inserted -sheet motif (referred to as the  domain)
and a C-terminal -helix (Scott et al., 2005a; Xiao et al., 2007).
Like other AAA ATPases, VPS4 is thought to function as
an oligomeric ring. VPS4 is primarily a monomer or dimer in
the cytoplasm, and its assembly into a ring is enhanced by
interaction of its  domain with the cofactor LIP5 (Vta1 in
yeast; Scott et al., 2005a; Azmi et al., 2006; Vajjhala et al., 2006;
Hartmann et al., 2008; Yu et al., 2008).
LIP5/Vta1 is a 300 amino acid long highly charged
protein. Deletion of Vta1 in yeast leads to defects in cargo
sorting and vacuolar morphology (Shiflett et al., 2004) and
knockdown of LIP5 in mammalian cells significantly impairs
receptor down-regulation and viral budding (Ward et al.,
2005). A conserved domain at the C-terminus of LIP5 (the
“VSL (Vta1/SBP1/LIP5) domain”) mediates LIP5 dimeriza-
tion and interaction with Vps4 (Azmi et al., 2006).
In addition to binding to VPS4, LIP5/Vta1 has been found
to interact with CHMP5/Vps60, one of the proposed regu-
latory ESCRT-III proteins (Shiflett et al., 2004; Ward et al.,
2005; Azmi et al., 2006; Rue et al., 2007). This interaction is
robust and has been documented in many systems. Less well
explored connections between Vta1 and a few other ESCRT-
III–related proteins have been reported, primarily in yeast.
In particular, Vta1 binds to Did2/Vps46 (yeast ortholog of
CHMP1; Lottridge et al., 2006) and the name Vta1 (Vps
twenty [Vps20]–associated 1) was originally derived from a
connection between Vps20 and Vta1, although this interac-
tion has not been reproduced (Yeo et al., 2003; Azmi et al.,
2006).
In the present study, we directly examine the ability of
LIP5 to bind each of the six classes of ESCRT-III–related
proteins in order to determine whether ternary interactions
between LIP5, VPS4, and ESCRT-III might play a role in
ESCRT-III disassembly. We confirm that LIP5 binds to
CHMP5, but also find that it binds to CHMP1B, CHMP2A,
and CHMP3 but not to CHMP4A or CHMP6. Mapping the
binding sites reveals that LIP5 binds to the extreme C-
terminal region of CHMP1B and CHMP2A and instead to an
internal sequence in CHMP5. Complexes of LIP5 with
CHMP5 are preferentially soluble, whereas those between
LIP5 and CHMP2A are polymeric and insoluble. The C-
terminal binding site for LIP5 in CHMP1B and CHMP2A
overlaps with the previously defined “MIT interacting mo-
tif” or MIM responsible for recruiting Vps4. Surprisingly, we
find evidence of a second binding site for VPS4 within these
ESCRT-III proteins that may allow them to simultaneously
interact with VPS4 and LIP5. These studies suggest that LIP5
is deeply intertwined with ESCRT-III and VPS4 in the path-
way leading to multivesicular body formation.
MATERIALS AND METHODS
Plasmids
The following ESCRT-III and VPS4 constructs have been previously de-
scribed: pGEX4T-1 CHMP4A residues 1-222; pHO4d VPS4B(E235Q)-His6/
myc; pEGFP C1 VPS4B(E235Q); pcDNA3.1 FLAG-CHMP4A 1-222, 1-181,
1-147; and pGEX4T-1-CHMP2A 1-222, 1-180, and 1-144 (Lin et al., 2005; Shim
et al., 2007). ESCRT-III and VPS4 constructs prepared for this study include
pGEX4T-1-CHMP6 1-201; pGEX4T-1-CHMP3 1-222; pGEX4T-1-CHMP2A
1-219, 1-216, 1-203, and 1-193; pGEX4T-1-CHMP1B 1-199, 1-181, 106-199,
106-181, and 169-199; pGEX4T-1-CHMP5 1-219, 121-149, 121-158, 121-175, 121-
219, 149-175, and 149-183; pcDNA3.1-FLAG-CHMP2A 1-219, 1-206, and 1-193;
pcDNA3.1-FLAG-CHMP1B 1-199, 1-181, 1-168, and 1-136; pcDNA3.1-FLAG-
CHMP5 1-219; pcDNA4TO-CHMP5 1-219 His6myc; pET28a-VPS4A MIT domain
(1-75); and pGEX4T-1-VPS4B(E235Q) and pGEX4T-1-VPS4B(E235Q, GAI
deletion of 390-396). cDNAs used to create these constructs were either from
the Mammalian Genome Collection (human CHMP1B, CHMP2B, and
CHMP5; IMAGE ID: 6165059, 3460712, and 4094210, respectively) or previ-
ously described (CHMP2A, CHMP3, CHMP4A, and CHMP6; Lin et al., 2005;
Shim et al., 2007). For insertion into pGEX4T-1, pcDNA3.1-FLAG, pcDNA4/
TO-His6myc or pET28a, BamHI and XhoI sites were added to the fragments
as they were amplified by PCR. QuickChange (Stratagene, La Jolla, CA)
site-directed mutagenesis was used to introduce point mutations into
CHMP2A and CHMP1B as indicated in the text.
pEGFP C1-LIP5 was a kind gift from Dr. Jerry Kaplan (University of Utah, Salt
Lake City, UT). For bacterial expression of His6-LIP5, PCR amplified cDNA was
inserted into pET28a between NdeI and XhoI sites. GFP-LIP5 N contains
residues 76-307 in pEGFP C1 between BglII and HindIII sites. All constructs were
sequenced using ABI big dye reagents at the Nucleic Acid Chemistry Laboratory
(Washington University, St. Louis, MO).
Protein Expression and Purification
BL21(DE3) Escherichia coli transformed with the indicated constructs were
grown at 37°C to a 600 nm optical density of 1, transferred to room
temperature, and brought to 0.4 M IPTG for 3 h to induce expression.
Pelleted bacteria were resuspended in buffer A (20 mM Tris, 250 mM NaCl,
5% glycerol, 1 mM DTT, 1 mM PMSF, pH 7.4) and lysed by sonication.
Bacterial lysates were centrifuged at 66,000  g for 20 min. Clarified lysates
were bound to glutathione Sepharose (Amersham Biosciences, Piscataway,
NJ) or Ni2-NTA agarose (Qiagen, Valencia, CA) for 1 h at 4°C. Unbound
material was removed by washes in buffer A, and proteins were eluted in
buffer A containing either glutathione (50 mM) or imidazole (160 mM).
Purified protein was quantitated using Bradford reagent with BSA as a
standard. Proteins were snap-frozen in liquid nitrogen and stored at 80°C.
GST Pulldown Assays
Where indicated, GST proteins immobilized on beads were combined with
clarified bacterial lysate containing His6-LIP5. This lysate was prepared from
BL21(DE3) E. coli expressing pET28a-LIP5 grown as above. Bacteria were
lysed in buffer B (30 mM HEPES, 120 mM NaCl, 5% glycerol, 1 mM PMSF, pH
7.4), brought to 0.5% Triton X-100, and centrifuged at 66,000  g for 20 min.
Clarified bacterial lysate was incubated with immobilized glutathione S-
transferase (GST) fusion proteins for 1 h at 4°C in buffer B. Beads were
washed, and bound material was analyzed by SDS-PAGE and staining with
Coomassie brilliant blue. For the experiment shown in Figure 6B, GST pro-
teins were combined with mammalian cell lysate containing green fluorescent
protein (GFP)-LIP5. This was prepared from HEK293T cells transfected with
pEGFP C1-LIP5 solubilized in buffer B containing 0.5% Triton X-100 and
centrifuged at 15,000  g for 15 min. After the binding reaction, bound and
unbound material was detected by SDS-PAGE and immunoblotting with
rabbit anti-GFP antibody (Lin et al., 2005; 1:2500).
To assess competition between LIP5 and the VPS4A MIT domain, GST
proteins immobilized on glutathione Sepharose were blocked in buffer C (20
mm Tris, pH 7.8, 100 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 5 mM DTT, 5%
glycerol) also containing 1% casein for 1 h. Beads were incubated with
His6-LIP5 (0.4–12.8 M) with or without 300 M His6-VPS4A MIT domain
(CHMP2A) and with or without 500 M MIT domain (CHMP1B) for 1 h at
4°C. Control experiments were carried out with or without 300 M ribonu-
clease A. Beads were then washed three times in buffer C. Bound proteins
were analyzed by SDS-PAGE. Gels were stained with colloidal Coomassie (G
Biosciences, St. Louis, MO) and visualized using an Odyssey Infrared imager
(LiCor Biosciences, Lincoln, NE). Bands were quantified with Odyssey 2.1
software and were within the experimentally determined linear range of
detection.
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Solid-Phase LIP5-binding Assay
Microtiter plate wells containing immobilized antibody against GST (Pierce,
Rockford, IL, or EMD Biosciences, Gibbstown, NM) were incubated with 100
l of the indicated GST-ESCRT-III or GST-VPS4B protein at 10 g/ml for 1 h
in buffer D (20 mm Tris, pH 7.4, 150 mM NaCl, pH7.4; estimated to be
60–100 times the binding capacity of the plate as per manufacturer data).
For VPS4 binding assays, buffer D contained 100 mM KOAc in place of NaCl,
5 mM MgCl2, and 1 mM ATP. Plates were washed three times in buffer D with
0.05% Tween-20 and blocked for 1 h in buffer containing 1% casein (Pierce
plates) or 1% casein  0.5% BSA (EMD plates). Plates were then washed, and
100 l of His6-LIP5 at the indicated concentration in buffer D was added and
incubated for 1 h. Plates were again washed with buffer D, and 100 l of a
1:2000 dilution of NTA-horseradish peroxidase (HRP; Qiagen) was bound for
1 h. After washing, 100 l of TMB-Ultra (Pierce) was added to wells for 3
min. Absorbance was read at 652 nm on a Bio-Tek plate reader. Background
signal arising from nonspecifically bound His6-LIP5 (measured in parallel
wells containing no GST protein or GST alone) was subtracted from each
value. The background was concentration dependent, and in a typical assay
ranged from ABS of 0.1 for 4 nM His6-LIP5-0.23 for 3 M His6-LIP5. Corrected
absorbance data were analyzed using Prism (GraphPad, San Diego CA) to
define an EC50 by nonlinear regression analysis using the formula ABS 
(ABSmax  X)/(EC50  X).
Tissue Culture and Transfection
HEK293T cells were grown in DMEM (Invitrogen-BRL, Gaithersburg, MD)
containing 5% fetal bovine serum (Invitrogen-BRL), 5% supplemented calf
serum (Hyclone Laboratories, Logan, UT) and 2 mM glutamine. Cells were
transfected with the indicated plasmid(s) using Lipofectamine 2000 (Invitro-
gen, Carlsbad CA) following the manufacturer’s instructions and then used
for experiments 18–24 h after transfection.
Sedimentation Assay
Sedimentation assays were performed as described previously (Shim et al.,
2007). Briefly, transiently transfected HEK293T cells in 6-cm dishes were
solubilized in 1% Triton X-100 and centrifuged at 10,000 g for 15 min at 4°C.
Pellets were resuspended to the same volume as supernatant in lysis buffer,
and equal volumes of the fractions were analyzed by immunoblotting with
rabbit anti-FLAG antibody (Sigma, St. Louis MO, 1:2500) or rabbit anti-GFP.
Immunoprecipitation
Transiently transfected HEK293T cells in 6-cm dishes were solubilized in 500
l buffer E (0.5% Triton X-100, 30 mM HEPES, 120 mM NaCl, 1 mM PMSF and
complete protease inhibitor; Roche Diagnostics, Alameda, CA). Insoluble
material was removed by centrifugation at 15,000  g for 15 min. Soluble
lysate was incubated with 20 l of protein A Sepharose CL-4B (GE Health-
care, Piscataway, NJ) for 25 min to remove nonspecifically interacting mate-
rial, then with 6 l of rabbit anti-GFP antibody for 2 h, and finally with 30 l
of protein A Sepharose for 1 h, all at 4°C. Bound protein and lysate were
analyzed by immunoblotting using mouse monoclonal anti-myc (Develop-
mental Studies Hybridoma Bank, Iowa City, IA, 1:2500) and rabbit anti-GFP.
RESULTS
LIP5 Binds Tightly to Several ESCRT-III Proteins in
Addition to CHMP5
The AAA ATPase VPS4 plays a key role in MVB biogen-
esis (Babst et al., 1997, 1998; Babst et al., ; Bishop and Wood-
man, 2000; Fujita et al., 2003), but precisely what it does and
how this is regulated remains unclear. To gain new insight
into this reaction, we explored connections between ESCRT-
III and a known cofactor of VPS4, LIP5. A previous study
demonstrated that LIP5 bound efficiently but apparently
uniquely to the ESCRT-III like protein CHMP5 (Ward et al.,
2005); this interaction was also found in a reciprocal immu-
noprecipitation of proteins that bind to CHMP5 (Ma et al.,
2007). In yeast, Vta1p, the LIP5 orthologue, binds both to
Vps60p (CHMP5 ortholog; Shiflett et al., 2004; Azmi et al.,
2006; Rue et al., 2007) and to Did2p/Vps46p (CHMP1 or-
tholog; Lottridge et al., 2006). On this basis, we asked
whether LIP5 also interacts with other human ESCRT-III
proteins. We expressed ESCRT-III proteins representing
each of the ESCRT-III subfamilies as GST-fusion proteins in
E. coli and carried out in vitro binding experiments. In a
survey GST pulldown, we found that CHMP1B, CHMP2A/
hVps2-1, and CHMP3/hVps24 all bound to His6-LIP5,
whereas CHMP4A/hSnf7–1 and CHMP6/hVps20 did not
(Figure 1A).
To quantitatively compare binding of LIP5 to these differ-
ent proteins, we immobilized each GST-CHMP fusion pro-
tein on microtiter plates using anti-GST antibodies and mea-
Figure 1. LIP5 binds to ESCRT-III proteins. (A) Interaction of LIP5
with a subset of ESCRT-III proteins. GST and GST-ESCRT-III pro-
teins immobilized on glutathione-Sepharose beads were incubated
with E. coli lysate containing His6-LIP5. Bound material was sepa-
rated on a SDS-PAGE gel and stained with Coomassie blue. Where
necessary, lanes were rearranged as indicated by white lines. Im-
munoblotting with an anti-His6 antibody confirmed that no His6-
LIP5 bound to GST-CHMP4A or GST-CHMP6 (not shown). (B)
Solid phase assay of LIP5 binding to GST-CHMP1B, 2A, and 3.
His6-LIP5 bound to immobilized GST-CHMP proteins was detected
with NTA-HRP and TMB colorimetric substrate. EC50 values deter-
mined by nonlinear regression analysis ranged from 10 to 20 nM for
CHMP1B (Œ, solid line), from 49–60 nM for CHMP2A (E, dotted
line), and from 0.3–1 M for CHMP3 (, alternating dashed line) in
several independent experiments. Error bars, the SD from one ex-
periment run in duplicate. Absorbance data were normalized to the
Bmax for CHMP1B. (C) Binding of His6-LIP5 to GST-VPS4B(E235Q)
and GST-VPS4B(E235Q, GAI)  domain mutant. EC50 for VPS4B
(E235Q) (, solid line) was 60 nM. LIP5 binding to VPS4B(E235Q,
GAI) did not change as a function of LIP5 added (Œ, dotted line).
Error bars, the SD from one experiment run in duplicate, and the
absorbance data were normalized to the Bmax for VPS4B(E235Q).
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sured binding of His6-LIP5 across a range of concentrations
using Ni2-NTA conjugated to HRP and a colored substrate
to detect bound His6-LIP5. EC50 values for LIP5 binding
ranged from 10 to 20 nM for binding to GST-CHMP1B to
0.3–1 M for binding to GST-CHMP3 (Figure 1B). There was
no binding above background to immobilized GST, GST-
CHMP4A, or GST-CHMP6 (data not shown).
For comparison, we also quantitated the interaction of
LIP5 with VPS4B. These two proteins have previously been
shown to bind each other with an EC50 of 53 nM in surface
plasmon resonance experiments (Fujita et al., 2004). We
found that His6-LIP5 bound to immobilized GST-
VPS4B(E235Q) with an EC50 of 60 nM (Figure 1C) and that
this binding was abolished by a short deletion within the
VPS4B  domain (390–396) known to block interaction of
yeast Vps4 and Vta1 (Vajjhala et al., 2006; Figure 1C). We
conclude that LIP5 binds with submicromolar affinity to
both a subset of ESCRT-III proteins and to VPS4B. As will be
described below, we confirmed in parallel studies that
LIP5 also binds to CHMP5 with comparable or even
higher affinity (see Figure 8). The interaction of LIP5 with
CHMP1B might have been anticipated based on earlier
studies in yeast (Lottridge et al., 2006), but the association
of LIP5 with the core ESCRT-III proteins CHMP2A and
CHMP3 was unexpected and raises the possibility of a
more intimate relationship between LIP5 and ESCRT-III
than previously appreciated.
LIP5 Binding to CHMP2A and CHMP1B Is Mediated by
C-Terminal Sequences
To understand how LIP5 binds to ESCRT-III proteins, we
began by looking for its binding site in the core ESCRT-III
protein CHMP2A. We examined interaction between LIP5
and a series of CHMP2A deletion proteins that lack one or
more of the protein’s predicted six -helices (Figure 2A), as
previously described (Shim et al., 2007). Because even the
shortest deletion from the C-terminus (leaving an 1–5
protein, residues 1-180) abolished binding, we generated a
series of smaller deletions from the C-terminus to determine
whether binding required 6 or sequences within the long
linker between 5 and 6. GST-CHMP2A fusion proteins
were purified from E. coli and combined with His6-LIP5 to
assess their interaction (Figure 2B). Removing three amino
acids from the C-terminus of CHMP2A (leaving residues
1-219) was not expected to significantly affect 6 and did not
change binding of LIP5. On the other hand, removing six or
more amino acids (thus perturbing or removing 6) abol-
ished interaction of CHMP2A with LIP5. Deleting 1 from
CHMP2A (leaving residues 56-222) did not perturb LIP5
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Figure 2. C-terminal sequences in CHMP2A
and CHMP1B are required for LIP5 binding.
(A) Predicted CHMP2A secondary structure
obtained using a neural network based algo-
rithm (http://www.compbio.dundee.ac.uk/
www-jpred/). Pink and blue boxes corre-
spond to predicted -helices with pI higher
than 8 and lower than 6, respectively. (B) Ef-
fects of deleting N- and C-terminal sequences
from CHMP2A on LIP5 binding. GST and
GST-CHMP2A proteins with the indicated se-
quences immobilized on beads were incubated
with E. coli lysate containing His6-LIP5. Bound
material was analyzed by staining with Coo-
massie blue. (C) Predicted CHMP1B secondary
structure. (D) Effects of deleting N- and C-
terminal sequences from CHMP1B on LIP5
binding. GST and GST-CHMP1B proteins with
the indicated sequences immobilized on beads
were incubated with E. coli lysate containing
His6-LIP5. Bound material was analyzed by
staining with Coomassie blue (top panel) and
by immunoblotting with an anti-His6 antibody
(bottom panel). Immunoblotting was needed
because His6-LIP5 migrates similarly to GST-
CHMP1B(106-199).
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binding, demonstrating that the interaction is independent
of CHMP2A’s N-terminus.
In further experiments, we found the same requirement for
extreme C-terminal sequences for interaction of CHMP1B with
LIP5 (Figure 2C). Removing the predicted 6 from CHMP1B’s
C-terminus disrupted LIP5 binding, whereas deleting the N-
terminal half of the protein had no effect (Figure 2D). These
experiments demonstrate that sequences within 6 are needed
for CHMP2A and CHMP1B to bind LIP5.
Because deleting sequences from ESCRT-III proteins sig-
nificantly changes their conformation (Shim et al., 2007),
there remained the possibility of deletions indirectly impair-
ing binding to a site or sites located elsewhere in the protein.
To rule this out, we carried out additional experiments. We
started by changing a single conserved residue within 6 of
CHMP2A from leucine to alanine (L216A). This mutation
significantly decreased binding to LIP5 (Figure 3A). A com-
parable leucine residue in other ESCRT-III proteins has pre-
viously been shown to be important for binding of VPS4B to
CHMP1B (Stuchell-Brereton et al., 2007) and binding of Alix
to CHMP4 (von Schwedler et al., 2003), pointing to a likely
common role for the surface of 6 in binding between
ESCRT-III proteins and other factors.
To ask whether the C-terminal region is by itself sufficient
for interaction of these ESCRT-III proteins with LIP5, we
expressed 6 and surrounding linker sequences from
CHMP1B (169-199) as a GST fusion protein and asked if it
could bind to LIP5. Indeed, LIP5 bound to this 31-amino acid
fragment (Figure 3B) with an EC50 of 25 nM (Figure 3C),
similar to what we observed above for full-length CHMP1B.
These results argue that all of the determinants needed for
LIP5 binding are encoded within the C-terminal regions of
these ESCRT-III proteins.
Studies in Mammalian Cells Suggest That ESCRT-III
Interaction with LIP5 May Be Regulated by ESCRT-III
Assembly Status
As mentioned above, the high-affinity binding of LIP5 to the
core ESCRT-III protein CHMP2A was entirely unexpected.
Indeed, this finding is at first glance inconsistent with a
published report in which endogenous LIP5 was not immu-
noisolated with overexpressed CHMP2A from transfected
mammalian cells (Ward et al., 2005). We therefore examined
interaction of LIP5 with CHMP2A in HEK293T cells tran-
siently transfected with tagged versions of each protein.
When we immunoprecipitated FLAG-CHMP2A from the
solubilized lysate of doubly transfected cells, we also did not
recover significant amounts of LIP5 (data not shown). How-
ever, we noticed that overexpressed FLAG-CHMP2A had a
strong tendency to form large complexes or aggregates that
were insoluble in Triton X-100 and therefore pelleted during
preparation of the solubilized lysate. Although LIP5-GFP
expressed alone is soluble, we found that when coexpressed
with CHMP2A it associated with this insoluble material
(Figure 4A). LIP5 remained soluble when coexpressed with
CHMP2A fragments lacking their 6 region despite the fact
that the CHMP2A proteins still sedimented. In addition,
LIP5 only associated with pelleted CHMP2A when its N-
terminus—previously shown in yeast to mediate interaction
with the ESCRT-III–related protein Vps60—was intact.
Parallel studies with cells transfected with CHMP1B and
LIP5-GFP demonstrated that CHMP1B similarly recruited
LIP5 to sedimentable complexes only when its 6 region was
intact (Figure 4B). These results are consistent with our
analysis of recombinant proteins above and confirm that
LIP5 binds to extreme C-terminal sequences in CHMP2A
and CHMP1B. Based on our earlier study of ESCRT-III ho-
mopolymers (Shim et al., 2007), the preferential association
of LIP5 with pelleted CHMP2A and CHMP1B suggests that
LIP5 may bind to these proteins in their “open” conforma-
tion and tend to stabilize this state.
LIP5 and VPS4 MIT Binding Sites Overlap in CHMP2A
and CHMP1B
Interestingly, the extreme C-terminal regions of CHMP2A
and CHMP1B were recently shown to contain a short -helix
that binds to VPS4 via a twelve residue sequence referred to
as the MIT interaction motif (MIM; Obita et al., 2007; Stuch-
ell-Brereton et al., 2007). The MIM helix largely coincides
with the sequence we defined as 6 by secondary structure
prediction (Shim et al., 2007). We found above (Figure 3A)



























Figure 3. CHMP2A and CHMP1B 6 region is responsible for LIP5
binding. (A) Effect of CHMP2A L216A mutation on interaction with
LIP5. GST and GST-CHMP2A proteins immobilized on beads were
incubated with E. coli lysate containing His6-LIP5. Bound material
was analyzed by staining with Coomassie blue. Where necessary,
gel lanes were rearranged as shown by a white line. (B) Binding of
His6-LIP5 to GST-CHMP1B(169-199). This CHMP1B fragment con-
tains 6 and surrounding sequences but does not include 5. (C)
Solid phase assay of His6-LIP5 binding to GST-CHMP1B(169-199)
carried out as described in Figure 1. The EC50 of 25 nM is similar
to that of His6-LIP5 for full-length CHMP1B. Absorbance data
were normalized to the Bmax for full-length CHMP1B measured
in parallel.
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that mutating a conserved hydrophobic residue in this helix
reduced binding of LIP5 to CHMP2A. This impairment is in
accordance with the reported 10-fold decrease in VPS4 bind-
ing when the equivalent change was made in CHMP1B
(Stuchell-Brereton et al., 2007). VPS4 and LIP5 may therefore
share elements of a common binding site in these ESCRT-III
proteins.
To determine if this is the case, we asked whether the
VPS4 MIT domain competes with LIP5 for binding to
CHMP2A and CHMP1B. We expressed and purified the
His6-tagged MIT domain of VPS4A from E. coli and added it
to GST pulldown experiments (Figure 5A). We found that
high concentrations of the MIT domain reduced but did not
abolish binding between LIP5 and both CHMP2A and
CHMP1B (Figure 5B). Parallel control experiments demon-
strated that adding 300 M ribonuclease A had no effect on
LIP5 binding (Figure 5, A and C).
Given this apparent overlap in binding sites, the question
of how the affinity of these ESCRT-III proteins for LIP5
compares with that for VPS4 becomes important. We were
unable to quantitate VPS4B (full-length or MIT domain)
binding to immobilized GST-ESCRT-III proteins because of
high background in the microtiter plates. In recent studies
of VPS4 MIT domain binding to ESCRT-III MIM frag-
ments the observed EC50 values were significantly higher
(i.e., lower affinity) than those we measured between LIP5
and full-length ESCRT-III proteins (Obita et al., 2007;
Stuchell-Brereton et al., 2007). For a first assessment of the
relative ability of VPS4 and LIP5 to bind to their shared
binding site, we compared binding of full-length proteins
to GST-CHMP1B(169 –199) (Figure 5D). After incubating
this 6 fragment with 5 M His6-VPS4B(E235Q) or His6-
LIP5, we recovered similar amounts of bound protein,
suggesting that full-length VPS4B and LIP5 may have
similar affinity for the MIM-containing ESCRT-III pro-
teins.
A Second Binding Site for VPS4 in ESCRT-III Proteins
If VPS4 and LIP5 have overlapping binding sites in this
subset of ESCRT-III proteins, how do they function to-
gether? One possibility is that the C-terminal 6 se-
quences, preferentially exposed when the proteins assem-
ble into ESCRT-III complex, cooperate to bring VPS4 and
LIP5 together. Another, not mutually exclusive, possibility is
that the interaction between 6 sequences and these proteins
is only one step in the reaction leading to ESCRT-III disas-
sembly, with additional steps and interactions required. On
the basis of what is known about other AAA proteins, we
wondered whether there might be a second, yet unidenti-
fied, binding site for VPS4 within ESCRT-III proteins. If so,
this might also enable simultaneous interaction of ESCRT-III
with VPS4 and LIP5.
To search for such a binding site, we took advantage of the
fact that the detergent insoluble polymers formed when
CHMP proteins are overexpressed in mammalian cells (see
Figure 4) create a high avidity matrix for their binding partners.
We carried out sedimentation assays using HEK293T cells
coexpressing CHMP2A deletion mutants and VPS4B(E235Q).
Similar to what we saw with LIP5, coexpressed VPS4B
(E235Q) sedimented with full-length CHMP2A (Figure 6A).
Interestingly, however, small C-terminal deletions (includ-
ing the MIMs) that eliminated interaction between CHMP2A
and LIP5 did not affect association of VPS4B(E235Q) with
CHMP2A. On the other hand, further deleting 5 and sur-
rounding sequences abolished the CHMP2A dependent re-
cruitment of VPS4B(E235Q). Note that the basal association
of VPS4B(E235Q) with the insoluble fraction is somewhat
higher than that of LIP5, presumably because VPS4B(E235Q)
traps and binds to polymerized endogenous ESCRT proteins
(Lin et al., 2005). Similar results were obtained with
CHMP1B and VPS4B(E235Q) (Figure 6B), suggesting that
there might be a secondary binding site for VPS4 around or
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Figure 4. LIP5 associates preferentially with poly-
merized CHMP2A and CHMP1B in transfected
mammalian cells. (A) Cosedimentation of LIP5 with
CHMP2A. HEK293T cells cotransfected with GFP-
LIP5 or GFP-LIP5N, and the indicated FLAG-
CHMP2A constructs were solubilized in 1% Triton
X-100 and centrifuged. The distribution of CHMP2A
and LIP5 in the resulting supernatant (S) and pellet
(P) was visualized by immunoblotting. LIP5N is
equivalent to a deletion in Vta1 that impairs binding
to Vps60 (Azmi et al., 2006). Experiments with
LIP5N were performed separately from those with
full-length LIP5 and are therefore shown in a sepa-
rate box. (B) Cosedimentation of LIP5 with CHMP1B.
The same experiments performed with FLAG-
CHMP1B constructs.
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within the predicted 5 helix of both proteins. The orthog-
onal and exposed position of 5 in the currently available
crystal structure of CHMP3 (Muziol et al., 2006) suggests
that this helix may move as a function of ESCRT-III confor-
mation, making it an attractive candidate for engaging VPS4.
Our initial attempts to define this potential binding site
more precisely using purified proteins in GST pulldown
experiments failed, both because the affinity of this interac-
tion appears to be low and because the nonspecific binding
of VPS4B to truncated ESCRT-III proteins was variable and
relatively high.
To gain additional insight into the nature of this binding
site, we instead turned to site-directed mutagenesis in our
cell-based sedimentation assay. We noted that the region
within and around 5 is highly acidic in all ESCRT-III pro-
teins and contains a glutamic acid that is the only residue
conserved among all ESCRT-III proteins (Muziol et al., 2006;
Figure 7A). To determine if this region is involved in the
secondary association of VPS4B with ESCRT-III proteins, we
replaced pairs of acidic residues within and around 5 in
CHMP2A with alanines. One pair included the conserved
glutamic acid (mut a), and the others (mut b and mut c) were
nearby but less conserved pairs. We also replaced the con-
served pair of acidic residues (mut a) in CHMP1B. We made
these mutations in both full-length and 6-deleted proteins,
with the prediction that association of VPS4B with the full-
length proteins would be mediated largely by their MIM
and would therefore be independent of a secondary binding
site, whereas association of VPS4B with the truncated (6-
deleted) proteins would instead be fully dependent on the
secondary binding site. Strikingly, we found that mut a
eliminated recruitment of VPS4B(E235Q) to 6-deleted but
not full-length CHMP2A (Figure 7B). Mut b and mut c had
no effect. The fact that mut a did not affect recruitment of
VPS4B to polymers of full-length CHMP2A confirms that
the alanine replacements did not induce significant protein
misfolding. In support of these results, we found the same
effect of mut a replacements on the recruitment of VPS4B
(E235Q) to CHMP1B (Figure 7C). We conclude that con-












































































Figure 5. Binding sites for VPS4 and LIP5 in
CHMP2A and CHMP1B overlap. (A) VPS4A
MIT domain reduces LIP5 binding to GST-
CHMP2A. GST-CHMP2A was incubated with
His6-LIP5 alone or together with 300 M His6-
VPS4A MIT domain or ribonuclease A as indi-
cated. Bound LIP5 was visualized by staining
with colloidal Coomassie blue and quantified
by infrared fluorescence scanning. The bound
MIT domain can be seen as an increased inten-
sity in the dye front. (B) Quantitation of the
effect of MIT domain on binding of 3.2 M
LIP5 to CHMP2A or (in parallel experiments)
CHMP1B. (C) Quantitation of lack of effect of
the same concentration (300 M) of ribonucle-
ase A on binding of 1.6 M LIP5 to GST-
CHMP2A. (D) LIP5 and VPS4B(E235Q) bind
similarly to GST-CHMP1B(169-199). Material
retained on GST or GST-CHMP1B(169-199) af-
ter incubation with the indicated 5 M protein
is shown on a gel stained with Coomassie Blue.
Interactions between LIP5 and ESCRT-III Proteins
Vol. 19, June 2008 2667
component of the secondary VPS4 binding site. Because
these experiments were carried out in cells that highly over-
express VPS4B and the ESCRT-III protein in question, we
consider it unlikely but cannot exclude that an intermediate
protein such as Ist1 (Dimaano et al., 2008) mediates this
secondary interaction between VPS4 and the acidic 5 resi-
dues in ESCRT-III proteins.
LIP5 Complex with CHMP5 Is Unique
Finally, we wondered how the previously described inter-
action between LIP5 and CHMP5 (Ward et al., 2005) com-
pares to its binding to the MIM-containing ESCRT-III pro-
teins studied above. The fact that LIP5 and CHMP5 have
been reciprocally identified as binding partners in unbiased
pulldowns from cultured mammalian cell cytosol (Ward
et al., 2005; Ma et al., 2007), whereas none of the other
complexes have been detected, suggests that there could be
important differences. CHMP5 does not have a MIM, and in
fact its predicted secondary structure does not include
strong indication of a C-terminal helix comparable to 6 in
the other ESCRT-III proteins (Figure 8A). To characterize the
interaction between LIP5 and CHMP5, we began by per-
forming in vitro binding experiments. Our initial attempts to
use full-length GST-CHMP5 purified from E. coli were un-
successful because the protein was not well behaved, form-
ing aggregates that did not consistently bind to LIP5 (data
not shown). The C-terminal half of the protein (GST-CHMP5
121-219), however, was readily soluble and reproducibly
bound to LIP5 (Figure 8, B and C). In solid phase-binding
assays, we found that LIP5 bound to this C-terminal frag-
ment with an EC50 of 1–2 nM (Figure 8D), confirming an
even tighter interaction between CHMP5 and LIP5 than
between LIP5 and the other ESCRT-III proteins.
To define the structural requirements for interaction of
CHMP5 with LIP5, we made a series of GST-CHMP5 frag-
ments and tested their ability to bind to GFP-LIP5 present in
a transfected cell extract (Figure 8B). Deleting sequences
C-terminal to the predicted 5 helix (GST-CHMP5 121-175)
had little effect on binding, whereas removing the predicted
5 region (GST CHMP5 121-158 and 121-149) abolished LIP5
binding, suggesting an important role for 5. Indeed, a
27-residue fragment containing only linker sequences and
5 (GST CHMP5 149–175) bound to LIP5 as efficiently as the
longer fragments. Sequences within and around 5 are thus
both necessary and sufficient for binding of LIP5. To confirm
this result with purified proteins, we examined binding of
His6-LIP5 expressed in E. coli to the CHMP5 4  5 or 5
fragments. As was the case with GFP-LIP5 from mammalian
cell extracts, both fragments were able to bind efficiently to
LIP5, confirming that sequences within and around 5 are
responsible for high-affinity binding between these two pro-
teins (Figure 8C).
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Figure 6. Effects of C-terminal deletions suggest existence of sec-
ondary binding site for VPS4B in CHMP2A and CHMP1B. (A)
HEK293T cells cotransfected with VPS4B(E235Q)-GFP and indi-
cated FLAG-CHMP2A constructs were solubilized in 1% Triton
X-100 and centrifuged. The resulting distribution of VPS4B(E235Q)
and CHMP2A between supernatant (S) and pellet (P) was visual-
ized by immunoblotting. (B) Same experiment but with FLAG-
CHMP1B constructs.
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Figure 7. Conserved acidic residues in 5 are part of secondary
VPS4-binding site. (A) Sequences of predicted 5 and surrounding
sequences in CHMP2 and CHMP1 proteins. Highly conserved
acidic residues near the center of the helix are colored red; less
conserved pairs of acidic residues in CHMP2A are colored blue.
Pairs of alanine replacements in CHMP2A studied below are des-
ignated mut a, mut b, and mut c as indicated. The conserved central
pair of acidic residues was also mutated in CHMP1B and desig-
nated as mut a. (B) Effect of double alanine mutants on cosedimen-
tation of VPS4B(E235Q) with full-length (1-222) or 6-deleted (1-
206) CHMP2A in cotransfected HEK293 cells. Cells were solubilized
in 1% Triton X-100 and centrifuged. The resulting distribution of
VPS4B(E235Q) and CHMP2A between supernatant (S) and pellet
(P) was visualized by immunoblotting. (C) Effect of mut a on co-
sedimentation of VPS4B(E235Q) with full-length (1-199) or 6-de-
leted 1–5 (1-181) CHMP1B.
S. Shim et al.
Molecular Biology of the Cell2668
To further compare the interaction of LIP5 with CHMP5 to
that with CHMP1B or 2A, we again carried out a sedimen-
tation assay in cotransfected HEK293T cells. As seen previ-
ously for CHMPs 1B and 2A, a substantial portion of over-
expressed CHMP5 formed complexes or aggregates and
ended up in the pellet. Interestingly, however, this insoluble
material did not recruit LIP5, which was exclusively found
in the soluble fraction (Figure 8E). To confirm that soluble
CHMP5 actually interacts with LIP5 in these cells, we im-
munoprecipitated GFP-LIP5 and found that, as expected,
Figure 8. Unique properties of CHMP5-LIP5 complex: LIP5 binds to CHMP5 5 preferentially in the soluble fraction. (A) Predicted
secondary structure of CHMP5. (B) GST and GST-CHMP5 proteins immobilized on beads were incubated with HEK293T cell lysate
containing GFP-LIP5. Bound and unbound fractions were analyzed by immunoblotting with anti-GFP antibody. GST proteins were
visualized by staining the immunoblot with Ponceau red. (C) GST and GST-CHMP5 proteins on beads were incubated with E. coli lysate
containing His6-LIP5, and the bound material was analyzed by staining with Coomassie blue. Where necessary, lanes were rearranged as
indicated by white lines. (D) Binding of His6-LIP5 to immobilized GST-CHMP5(121-219), detected, and analyzed as in Figure 1B. EC50 values
ranged from 1 to 2 nM. Error bars, SD from one experiment performed in duplicate. (E) LIP5 does not cosediment with CHMP5. HEK293T
cells cotransfected with GFP-LIP5 and FLAG-CHMP5 were solubilizated in 1% Triton X-100 and centrifuged. The resulting supernatant (S)
and pellet (P) were analyzed by immunoblotting. (F) Coimmunoprecipitation of CHMP5-myc with LIP5-GFP from cotransfected HEK293T
cells. LIP5-GFP or LIP5N-GFP was immunoprecipitated from the soluble lysate of cotransfected cells. Bound proteins and lysate were
analyzed by immunoblotting.
Interactions between LIP5 and ESCRT-III Proteins
Vol. 19, June 2008 2669
FLAG-CHMP5 was efficiently recovered (Figure 8F). De-
leting the N-terminal 75 residues from LIP5 (LIP5N)
abolished this binding as it has been reported to do with
the comparable proteins in yeast (Azmi et al., 2006). To-
gether, our data suggest that LIP5 interacts with CHMP5
in a distinct manner that may or may not be compatible
with ESCRT-III polymer assembly.
DISCUSSION
LIP5 (Vta1 in yeast) emerged in recent years as a protein
involved in late stages of MVB formation and viral budding.
It participates in these events at least in part by binding via
its C-terminal “VSL domain” to the AAA ATPase VPS4 to
enhance oligomerization and ATPase activity (Scott et al.,
2005a; Azmi et al., 2006; Lottridge et al., 2006; Vajjhala et al.,
2006). At the same time, LIP5 also binds via its N-terminus
to the ESCRT-III–related protein CHMP5 (Vps60 in yeast;
Shiflett et al., 2004; Ward et al., 2005; Rue et al., 2007), and in
yeast Vta1 has been shown to bind to Vps46, another
ESCRT-III–related protein (Lottridge et al., 2006). Whether,
and if so how, these interactions affect VPS4 activity toward
ESCRT-III complexes has been unclear. Here, we define
new and unexpected relationships among these proteins,
including a high-affinity connection between LIP5 and the
C-termini of a subset of ESCRT-III proteins and a second
binding site for VPS4 further inside these proteins. In
addition, comparison of LIP5’s interaction with CHMP5
and the other ESCRT-III proteins revealed important dif-
ferences in where and how the proteins bind to each
other, suggesting the possibility of a unique role for
CHMP5. These findings lead us to propose that there are
at least two ways in which LIP5 is involved in ESCRT-III
disassembly.
LIP5 has been clearly shown to be a positive modulator of
the MVB sorting pathway. Reducing its expression by RNAi
decreases degradation of the EGF receptor and blocks HIV
viral particle release, whereas overexpressing it has no effect
(Ward et al., 2005). In yeast, mutations in VTA1 impair
membrane protein degradation and create a weak class E
phenotype, the severity of which may depend on the flux of
cargo through the endosomal pathway (Shiflett et al., 2004;
Azmi et al., 2006; Rue et al., 2007). Although LIP5’s known
role in VPS4 oligomerization might explain these effects, our
results reveal that LIP5 also directly and efficiently engages
a number of ESCRT-III proteins, including in particular
those that contain the C-terminal MIM known to bind VPS4
(Figures 1 and 2; Obita et al., 2007; Stuchell-Brereton et al.,
2007).
How might LIP5 bound to ESCRT-III proteins modulate
progress through the MVB pathway? Because LIP5 and
ESCRT-III are already thought to be cofactor and substrate
of VPS4, respectively, it is logical to think that their interac-
tion will affect VPS4 function. This idea is supported by the
fact that the same ESCRT-III proteins that bind well to VPS4
(CHMP1, CHMP2, and CHMP3) bind well to LIP5 (Howard
et al., 2001; Scott et al., 2005b; Nickerson et al., 2006; Obita
et al., 2007; Stuchell-Brereton et al., 2007). One possibility is
that the extra link between LIP5 and ESCRT-III complex
ensures that VPS4 oligomerizes only where it is needed. In
the simplest scenario, this would predict that interactions
between these three proteins would reinforce each other.
Indeed, VPS4 interacts with ESCRT-III and LIP5/Vta1 via
separate domains (Azmi et al., 2006; Vajjhala et al., 2006).
Similarly, LIP5/Vta1 binds to VPS4 and the ESCRT-III like
protein CHMP5/Vps60 via its C-terminus and N-terminus,
respectively (Azmi et al., 2006). However, we found that the
VPS4 MIT domain reduces LIP5 binding to both CHMP2A
and CHMP1B, indicating that everything cannot happen
simultaneously (Figure 5).
At the same time, we found evidence for a second, more
internal, binding site for VPS4 in these ESCRT-III proteins
(Figures 6 and 7), leading us to suggest that the interaction
of VPS4 with the MIM motifs in 6 may represent only one
step in ESCRT-III disassembly. Although we were unable to
precisely define the second VPS4 binding motif in vitro,
deletion and alanine scanning studies in both CHMP2A and
CHMP1B indicated that this interaction depends on con-
served sequences within these proteins’ 5 helix and in
particular on two acidic residues that are conserved across
ESCRT-III proteins. Interestingly, 5 occupies an exposed
position in the crystal structure of CHMP3 (Muziol et al.,
2006), which probably represents the “open” form of these
proteins (Saksena et al., 2007). We propose that interaction
of VPS4 – using its MIT domain, elements within its
AAA domain such as the “pore loops” known to be
important for its function (Scott et al., 2005a), or possibly
an associated cofactor such as the recently described Ist1
(Dimaano et al., 2008)—with 5 in all ESCRT-III proteins
is likely to be an important additional step in ESCRT-III
complex disassembly.
Although LIP5 is clearly established as a positive modu-
lator of the MVB sorting pathway, the role played by
CHMP5 (Vps60 in yeast) is less clear. CHMP5 binds with
high affinity to LIP5 (Figure 8), and deleting these two
proteins in yeast has overlapping rather than additive effects
(Rue et al., 2007). However, reducing or eliminating CHMP5
expression in mammalian tissues or cells does not prevent
formation of MVBs (nor incorporation of TGF- receptors
into the internal vesicles; Shim et al., 2006) and in fact en-
hances HIV budding from cells (Ward et al., 2005). These
effects, together with the fact that LIP5’s interaction with
CHMP5 is fundamentally different from its interaction with
the other ESCRT-III proteins, lead us to suggest that CHMP5
bound to LIP5 might negatively regulate LIP5 for engage-
ment with other ESCRT-III proteins and VPS4. This possi-
bility remains to be further explored.
A model that summarizes our results and how they im-
pact thinking about the cooperation between LIP5 and VPS4
in regulating ESCRT-III is shown in Figure 9. Binding sites
for LIP5 (5 in CHMP5 and 6 in CHMP1B and CHMP2A)
and for VPS4B (previously described primary site in 6,
secondary binding site in 5) are shown in Figure 9A. The
relationship between ESCRT-III subunits, ESCRT-III com-
plex, and LIP5 and VPS4 is depicted in Figure 9B. ESCRT-III
proteins are closed monomers in the cytosol. In this state,
our results suggest that only CHMP5 binds to LIP5. When
ESCRT-III proteins polymerize into complexes on the endo-
somal membrane (presumably nucleated by upstream fac-
tors that are connected to cargo) the subunits open, exposing
sequences at their C-termini for binding to LIP5 and/or
VPS4. How these two proteins share their overlapping bind-
ing sites remains to be determined, but their separate abil-
ity to bind each other (via domains that are not engaged
with the ESCRT-III proteins, the  domain in VPS4 (Scott
et al., 2005a; Vajjhala et al., 2006) and the VSL domain in
LIP5 (Azmi et al., 2006) is likely to reinforce their associ-
ation. Once some threshold is reached (perhaps full as-
sembly of a VPS4 oligomer; Hartmann et al., 2008; Yu
et al., 2008), we hypothesize that VPS4 engages its second-
ary contact site. This in turn may allow VPS4 to unfold
individual ESCRT-III subunits and release them into the
cytoplasm, where they revert to their closed and mono-
meric states. Although aspects of this model remain to be
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confirmed, and importantly any ESCRT-III disassembly
reaction has yet to be reconstituted, the intricacies of this
important step in MVB biogenesis are finally starting to
come into focus.
While this article was being reviewed and revised, two
articles examining the structure and interactions of Vta1 (the
yeast equivalent of LIP5) were published (Azmi et al., 2008;
Xiao et al., 2008). In one, the high-resolution crystal structure
of the Vta1 N-terminus revealed two MIT-like domains, each
consisting of three -helices (Xiao et al., 2008). This structure
strongly supports our finding of a high-affinity interaction
between LIP5 and the MIM-containing ESCRT-III proteins
CHMP1B and CHMP2A and suggests that one or both of
LIP5’s MIT domains binds to these proteins. In the second
article, the interaction between Vta1 and Vps60 (yeast
CHMP5) was explored in more detail with results that
largely agree with what we report here for mammalian
proteins (Azmi et al., 2008). Significant differences are the
failure to see a high-affinity interaction between Vta1 and
Vps2 in the yeast system and mapping of the Vta1 binding
site in Vps60 to 4 instead of 5 as found here for CHMP5
and LIP5. Whether these differences reflect differences in the
protein interactions or in the conditions used to study them
remains to be established.
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